With One in Four Adults Overweight, Are Weight-Loss Drugs the Game Changer in India’s Battle Against Obesity?

With one in four Indian adults now overweight, the country stands at a crossroads in its battle against obesity.

Once dismissed as a lifestyle issue, obesity is now recognized as a full-fledged health epidemic — one that’s driving up cases of diabetes, cardiovascular disease, and hypertension across age groups. But a new generation of weight-loss drugs could change how India confronts the crisis.

Medications like semaglutide and liraglutide — GLP-1 receptor agonists originally developed for diabetes — are being hailed as breakthrough treatments for effective, sustained weight loss. Globally known under brand names such as Ozempic and Wegovy, these drugs have become a phenomenon in the West. Now, as they begin to enter the Indian market, they’re sparking both enthusiasm and caution among doctors and patients alike.

Experts say the drugs could transform obesity management for those who’ve struggled to lose weight through diet and exercise alone. “Obesity is not just about willpower — it’s a chronic, complex condition involving metabolism and hormones,” says Mumbai-based endocrinologist Dr. Meera Bhatia. “These medications can help regulate appetite and insulin response, offering real hope for long-term results.”

Still, challenges remain. High costs — often ₹15,000 to ₹25,000 a month — put these drugs out of reach for most Indians. Moreover, doctors warn against unmonitored use, citing possible side effects such as nausea, dehydration, and nutritional deficiencies if misused.

At the same time, the conversation around body weight in India is beginning to evolve. The stigma attached to obesity is slowly giving way to a more nuanced understanding of health and self-care. As pharmaceutical innovation meets growing awareness, India may be on the verge of a medical and cultural shift — one where obesity is treated with science, compassion, and long-term vision rather than short-term fixes.